tiprankstipranks
Trending News
More News >
Summit Therapeutics (SMMT)
NASDAQ:SMMT
US Market
Advertisement

Summit Therapeutics (SMMT) Earnings Dates, Call Summary & Reports

Compare
1,631 Followers

Earnings Data

Report Date
Nov 05, 2025
After Close (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
-0.18
Last Year’s EPS
-0.08
Same Quarter Last Year
Based on 12 Analysts Ratings

Earnings Call Summary

Q1 2025
Earnings Call Date:May 01, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted several significant achievements, particularly the approval of ivonescimab in China and successful clinical trial results, indicating a promising outlook for Summit Therapeutics. Despite some concerns over increased operating expenses and uncertainty in OS benefit, the sentiment remains largely optimistic.
Company Guidance
During the Summit Therapeutics Q1 2025 earnings call, key guidance was provided regarding the ongoing development efforts and future prospects for their lead investigational asset, ivonescimab. The call highlighted several metrics related to clinical trials and financial performance. Ivonescimab recently received approval from China's NMPA as a frontline monotherapy for NSCLC with positive PD-L1 expression, backed by positive PFS results from the HARMONi-2 trial, showing a hazard ratio of 0.777, implying a 22% reduction in the risk of death compared to pembrolizumab. Additionally, Akeso’s HARMONi-6 trial met its primary endpoint with a statistically significant PFS improvement for ivonescimab plus chemotherapy. Summit expects top line data in mid-2025 from their global Phase III HARMONi trial in EGFR-mutated NSCLC, marking their first global registrational Phase III trial, which has received Fast Track designation from the U.S. FDA. Financially, Summit ended Q1 2025 with a cash position of approximately $361 million, while their non-GAAP R&D expenses remained stable at $47.1 million compared to the previous quarter. This robust financial standing supports the expansion of their commercial and clinical operations.
Ivonescimab Approval in China
Ivonescimab received approval from NMPA, the health authority in China, as frontline monotherapy treatment for patients with NSCLC whose tumors have positive PD-L1 expression. This approval is based on positive PFS results from Akeso's HARMONi-2 trial.
Positive Interim Analysis Results
An early interim analysis requested by the NMPA showed a clinically meaningful and strongly positive trend favoring ivonescimab with a hazard ratio of 0.777, implying a potential 22% reduction in the risk of death compared to pembrolizumab.
HARMONi-6 Phase III Trial Success
HARMONi-6 Phase III trial met its primary endpoint of progression-free survival, showing statistically significant and clinically meaningful improvement in PFS for ivonescimab plus chemotherapy against tislelizumab plus chemotherapy in advanced squamous NSCLC.
Expansion of Clinical Trials
Summit has initiated multiple global Phase III studies, including HARMONi-3 and HARMONi-7, evaluating ivonescimab in different settings of NSCLC. Additionally, collaborations with institutions like MD Anderson and Pfizer are expanding research into other cancer types.
Strong Financial Position
Summit ended Q1 2025 with a cash position of approximately $361 million and remains debt-free.

Summit Therapeutics (SMMT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

SMMT Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 05, 2025
2025 (Q3)
-0.18 / -
-0.08
Aug 11, 2025
2025 (Q2)
-0.09 / -0.76
-0.05-1420.00% (-0.71)
May 01, 2025
2025 (Q1)
-0.09 / -0.09
-0.06-50.00% (-0.03)
Feb 24, 2025
2024 (Q4)
-0.08 / -0.08
-0.05-60.00% (-0.03)
Oct 30, 2024
2024 (Q3)
-0.07 / -0.08
-0.03-166.67% (-0.05)
Aug 06, 2024
2024 (Q2)
-0.06 / -0.05
-0.021-138.10% (-0.03)
May 01, 2024
2024 (Q1)
-0.06 / -0.06
-1.4395.80% (+1.37)
Feb 20, 2024
2023 (Q4)
- / -0.05
-0.0728.57% (+0.02)
Nov 07, 2023
2023 (Q3)
- / -0.03
-0.1478.57% (+0.11)
Aug 09, 2023
2023 (Q2)
- / -0.02
-0.1787.65% (+0.15)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

SMMT Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 11, 2025
$28.25$25.68-9.10%
May 01, 2025
$24.67$27.90+13.09%
Feb 24, 2025
$22.12$18.84-14.83%
Oct 30, 2024
$21.83$18.65-14.57%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Summit Therapeutics (SMMT) report earnings?
Summit Therapeutics (SMMT) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).
    What is Summit Therapeutics (SMMT) earnings time?
    Summit Therapeutics (SMMT) earnings time is at Nov 05, 2025, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is SMMT EPS forecast?
          SMMT EPS forecast for the fiscal quarter 2025 (Q3) is -0.18.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis